The company, which develops treatments based on changes in the gut microbiome, has now raised $22m in total.
Enterome Bioscience, a France-based startup offering disease management solutions, has secured €10 million ($13.9m) in the first tranche of its series B round.
The round was led by Lundbeckfond Ventures, the corporate venturing subsidiary of pharmaceutical company Lundbeck, in conjunction with Natixis-backed venture firm Seventure Partners, both of which were existing investors. The round also saw participation from Omnes Capital.
Enterome Bioscience provides disease management solutions by recording, understanding and modifying the changes occurring in the gut microbiome. The gut…
